Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

98 Solvay Global Annual Report 2005 FINLAND Solvay Chemicals Finland Oy, Voikkaa SWEDEN 100 Ch Neopharma AB, Uppsala POLAND 100 Ph Fournier Polska Sp. z o.o., Warszawa 100 Ph Solvay Pharma Sp. z o.o., Piaseczno BULGARIA 100 Ph Solvay Bulgaria AD, Devnya CZECH REPUBLIC 100 Ch Solvay Alkor Folie Spol sr.o., Most RUSSIA 100 Pl Solvay Pharma OOO, Moscow UNITED STATES 100 Ph Solvay America, Inc., Houston, TX 100 - American Soda LLP, Parachute, CO 100 Ch Ausimont Industries, Inc., Wilmington, DE 100 Pl Fournier Pharma Corp, Inc., Parsippany NJ 100 Ph Girindus America, Inc., Cincinnati OH 74.1 Ch Girindus Sales Corporation, Tampa FL 74.1 Ch Girindus Corporation, Tampa FL 74.1 Ch Montecatini USA, Wilmington, DE 100 Pl Solvay Advanced Polymers, LLC, Alpharetta, GA 100 Pl Solvay Alkalis, Inc., Houston, TX 100 Ch Solvay America Funding Company, Houston, TX 100 - Solvay America Holdings, Inc., Houston, TX 100 - Solvay Automotive Plastics & Systems, Inc., Troy, MI 100 Pl Solvay Chemicals, Inc., Houston, TX 100 Ch Solvay Draka, Inc., Commerce, CA 100 Pl Solvay Engineered Polymers, Inc., Houston, TX 100 Pl Solvay Finance (America) Inc., Houston, TX 100 - Solvay Fluorides, LLC., Greenwich, CT 100 Ch Solvay HDPE, L.P., Houston, TX 100 Pl Solvay Information Technologies, LLC, Houston, TX 100 - Solvay PE, Inc., Houston, TX 100 Pl Solvay Polyolefi ns, Inc., Houston, TX 100 Pl Solvay Pharma U.S. Holdings, Inc., Houston, TX 100 Ph Solvay Pharmaceuticals, Inc., Marietta, GA 100 Ph Solvay Realty Holding LLC, Houston, TX 100 - Solvay Services LLC, Inc., Houston, TX 100 - Solvay Soda Ash Joint Venture, Houston, TX 80 Ch Solvay Soda Ash Expansion JV, Houston, TX 80 Ch Solvay Solexis, Inc., Wilmington, DE 100 Pl Unimed Pharmaceuticals Inc., Deerfi eld, IL 100 Ph
CANADA Fournier Pharma, Inc., Montreal 100 Ph Solvay Engineered Polymers (Canada), Inc., Concord 100 Pl Solvay Pharma, Inc., Scarborough 100 Ph Solvay Pharma Canada, Inc., Scarborough MEXICO 100 Ph Italmex S.A., Mexico 100 Ph Solvay Engineered Polymers Mexico S.A. de C.V., Monterrey 100 Pl Solvay Fluor Mexico S.A. de C.V.. Ciudad Juarez 100 Ch Solvay Mexicana S. de R.L. de C.V.. Monterrey 100 Ch Solvay Quimica Y Minera Servicios S.A. de C.V.. Monterrey 100 Ch Solvay Quimica Y Minera Ventas S.A. de C.V.. Monterrey BRAZIL 90 Ch Solvay Farma Ltda. Sao Paulo 100 Ph Solvay do Brasil Ltda. Sao Paulo 100 - Solvay Indupa do Brasil S.A.. Sao Paulo 62.7 Pl Solvay Quimica Ltda. Sao Paulo ARGENTINA 100 Ch Solvay Indupa S.A.I.C.. Bahia Blanca 62.7 Pl Solvay Argentina S.A.. Buenos Aires 100 - Solvay Quimica S.A.. Buenos Aires AUSTRALIA 100 Ch Fournier Pharma Australia Pty Ltd. Pymble 100 Ph Solvay Interox Pty Ltd. Banksmeadow 100 Ch Solvay Pharmaceuticals Pty Ltd. Pymble JAPAN 100 Ph Nippon Solvay KK. Tokyo 100 Ch Solvay Advanced Polymers KK. Tokyo 100 Pl Solvay Seiyaku KK. Tokyo 100 Ph Solvay Solexis KK. Minato Ku-Tokyo THAILAND 100 Pl Peroxythai Ltd. Bangkok SINGAPORE 83.9 Ch Solvay Singapour Pte Ltd. Singapore INDIA 100 - Solvay Pharma India Ltd. Mumbai CAYMAN ISLANDS 68.9 Ph Solvay Finance (Cayman) Ltd ,Georgetown 100 - Blair International Insurance (Cayman) Ltd, Georgetown SOUTH KOREA 100 - Solvay Fluor Korea Co. Ltd, Séoul 100 Ch Solvay Global Annual Report 2005 99
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46:
New Business Development Priority t
Page 47 and 48:
Meeting The Science Days organized
Page 49 and 50:
Human Resources The Group’s fi ve
Page 51 and 52: “ At the end of this seminar, all
Page 53 and 54: Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95 and 96: The following amounts relating to J
Page 97 and 98: PORTUGAL Fournier Farmaceutica Port
Page 99 and 100: List of fully consolidated Group co
Page 101: Solvay Salz Holding GmbH, Hannover
Page 105 and 106: GREAT BRITAIN Inergy Automotive Sys
Page 107 and 108: Summary fi nancial statements of So
Page 109 and 110: Statutory auditor’s report to the
Page 111 and 112: The Solvay share compared with the
Page 113 and 114: Contacts: The Investor Relations Te
Page 115 and 116: Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

Create successful ePaper yourself

Delete template?

Save as template?